Among patients with even minimal perfusion defects on quantitative single-photon emission computerized tomography (SPECT), the impact on risk of major adverse cardiovascular events (MACE) is significantly higher in those with diabetes, reports a study in Diabetes Care.

Women who take antibiotics for two months or longer are at increased risk of developing incident kidney stones later in life, suggests a study in American Journal of Kidney Diseases.

Sodium-glucose cotransporter-2 (SGLT2) inhibitors lower the risk of dialysis and other clinically important kidney outcomes in patients with type 2 diabetes, concludes a systematic review and meta-analysis in The Lancet Diabetes & Endocrinology.

Compared to white Americans, racial/ethnic minority groups have a higher prevalence of diabetes and prediabetes at a lower body mass index (BMI), reports a study in Diabetes Care.


A new integrative box risk prediction (iBox) score performs well in predicting long-term kidney allograft failure across countries and clinical settings, reports a study in the British Medical Journal.

The selective hydrochloric acid binder veverimer is a safe and efficacious treatment for metabolic acidosis in patients with CKD, according to a randomized trial report in the Lancet./kidneynews/11_10_11/44a/graphic/44af1.jpg

The sodium–glucose cotransporter-2 inhibitor empagliflozin may help prevent progression of chronic kidney disease (CKD) in patients with type 2 diabetes, independently of background medications that alter intrarenal hemodynamics, reports a study in Kidney International.

The post hoc exploratory analysis used data from the industry-sponsored BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) trial.


Wall boxes were found to be the source of contamination for an outbreak of gram-negative bloodstream infections (BSIs) at three dialysis facilities, according to a report in American Journal of Kidney Diseases.

Extreme heat events (EHE) are associated with increases in hospital admission and death for patients with kidney failure, reports a study in JAMA Network Open.


For patients with early CKD, non–vitamin K oral anticoagulants (NOACs) have a better risk-to-benefit profile than vitamin K antagonists (VKAs), concludes a meta-analysis in Annals of Internal Medicine.